# Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

> **NCT02593929** · EARLY_PHASE1 · WITHDRAWN · sponsor: **University of Pittsburgh**

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** ruxolitinib

## Key facts

- **NCT ID:** NCT02593929
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-01
- **Primary completion:** 2018-01
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02593929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02593929, "Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02593929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*